Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer-Reference-Cited by-同舟云学术

Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer

Published:2021-12 Issue:6 Volume:6 Page:100319
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Coleman N.,Hong L.,Zhang J.,Heymach J.,Hong D.,Le X.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference98 articles.

1. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol,2012

2. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials;Yang;Lancet Oncol,2015

3. Crizotinib in ROS1-rearranged non-small-cell lung cancer;Shaw;N Engl J Med,2014

4. First-line crizotinib versus chemotherapy in ALK-positive lung cancer;Solomon;N Engl J Med,2014

5. Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1);Drilon;Cancer Discov,2017

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alectinib Induced SJS/TEN: A Case Report and a Review;TURK ONCOL DERG;2024

2. Genomic and Immune Landscape Comparison of MET Exon 14 Skipping and MET-Amplified Non-small Cell Lung Cancer;CLIN LUNG CANCER;2024

3. Use of Oncogene Overlap by Tissue-Based Next-Generation Sequencing to Explore the Mutational Landscape and Survival Impact of HER2, KRAS and MET Copy-Number Gain in Non-Small Cell Lung Cancer;Clinical Lung Cancer;2024-09

4. Genomic and Immune Landscape Comparison of MET Exon 14 Skipping and MET-Amplified Non-small Cell Lung Cancer;Clinical Lung Cancer;2024-09

5. Prevalence and treatment of human epidermal growth factor receptor 2-altered non-small cell lung cancer: a retrospective analysis and systematic literature review;ecancermedicalscience;2024-08-01